Glycated Albumin (GA) is More Advantageous than Hemoglobin A1c for Evaluating the Efficacy of Sitagliptin in Achieving Glycemic Control in Patients with Type 2 Diabetes

Shima, Kenji; Komatsu, Machiko; Noma, Yukio; Miya, Keiko

doi:10.2169/internalmedicine.53.1364

Cited by 7 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…44,45 Since fructosamine reflects the average levels of blood glucose during the former 1 to 3 weeks, fructosamine would also expectedly mirror a poorly controlled glucose metabolism better than HbA1c. 40,46,47 Lindsey et al investigated fructosamine and HbA1c in a prospective, randomized, multicenter, controlled trial including 72 diabetic patients, 48 and showed that the combination of weekly fructosamine testing and daily blood glucose monitoring were no better than daily glucose monitoring alone. Subsequent studies demonstrated the utility of fructosamine and GA in diabetic patients who required tighter control, or in patients with conditions that rendered HbA1c testing unreliable such as gestational diabetes mellitus, postprandial hyperglycemia or gastric resection.…”

Section: Glycated Albumin and Fructosamine In Therapeutic Monitoring mentioning

confidence: 99%

See 1 more Smart Citation

Advantages and Pitfalls of Fructosamine and Glycated Albumin in the Diagnosis and Treatment of Diabetes

Danese

Montagnana

Nouvenne

et al. 2015

J Diabetes Sci Technol

162

139

View full text Add to dashboard Cite

Diabetes is one of the most severe and frequent human disorders. According to recent statistics, this condition afflicts as many as 382 million persons around the globe, with an estimated prevalence of approximately 8.3% in 2013. At variance with other frequent pathologies such as cardiovascular disease and bacterial infections, the trend toward an increased prevalence is not expected to soon reverse. Worldwide, as many as 592 million individuals may be affected by diabetes in 2035, a remarkable 55% increase in prevalence over the next 2 decades. 1 Due to its high global prevalence and severe, frequently life-threatening complications (eg, retinopathy, nephropathy, neuropathy, cardiovascular disease), diabetes must be regarded as a serious and increasing global health burden. The most recent Standards of Medical Care in Diabetes published by the American Diabetes Association (ADA) emphasize that early diagnosis and monitoring are critical for preventing or delaying the onset of acute complications and lowering the risk of long-term complications of diabetes. 2 The current diagnostic criteria for this condition are based on the presence of (1) glycated hemoglobin (HbA1c) value ≥6.5% (ie, ≥48 mmol/mol), (2) fasting plasma glucose (FPG) ≥126 mg/dL (ie, ≥7.0 mmol/L), (3) 2-hour plasma glucose ≥200 mg/dL (ie, ≥11.1 mmol/L) during an oral glucose tolerance test (OGTT) using a 75 g glucose load, or (4) random plasma glucose ≥200 mg/dL (ie, ≥11.1 mmol/L). An increased risk of diabetes (ie, prediabetes) is defined in the presence of (1) HbA1c value between 5.7-6.4% (ie, 39-46 mmol/mol), (2) FPG between 100-126 mg/dL (ie, 5.6-6.9 mmol/L), (3) 2-hour plasma glucose between 140-199 mg/ dL (ie, 7.8-11.0 mmol/L) during an OGTT. With regard to diabetes monitoring, the glycemic targets for nonpregnant adults with diabetes include HbA1c value <7.0% (ie, <53 mmol/mol), preprandial capillary plasma glucose between 567227D STXXX10.

show abstract

Section: Glycated Albumin and Fructosamine In Therapeutic Monitoring mentioning

confidence: 99%

Section: Clinical Studies About Glycated Albumin and Fructosaminementioning

confidence: 99%

Advantages and Pitfalls of Fructosamine and Glycated Albumin in the Diagnosis and Treatment of Diabetes

Danese

Montagnana

Nouvenne

et al. 2015

J Diabetes Sci Technol

162

139

View full text Add to dashboard Cite

show abstract

“…Glycated albumin has been shown to change faster than HbA1c in response to changes in medication or exercise. 67,68 Compared to HbA1c, glycated albumin is more strongly correlated with continuous glucose measurements over 1 to 2 days, 69,70 and may more accurately reflect long-term glycemic variability and glucose excursions. 71,72 …”

Section: Clinical Utility Of Nontraditional Markers Of Hyperglycemiamentioning

confidence: 99%

Beyond HbA1c and Glucose: the Role of Nontraditional Glycemic Markers in Diabetes Diagnosis, Prognosis, and Management

2014

View full text Add to dashboard Cite

Fasting glucose and hemoglobin A1c (HbA1c) are the standard measures for diagnosis and monitoring of diabetes. There has been recent interest in nontraditional markers of hyperglycemia, including fructosamine, glycated albumin and 1,5-anhydroglucitol (1,5-AG), as alternatives or adjuncts to standard measures. There is a growing literature linking these nontraditional markers with microvascular and macrovascular complications. Fructosamine and glycated albumin have also been shown to improve identification of persons with diabetes. However, long-term prospective studies with clinical outcomes are lacking. Some modern laboratory assays for fructosamine, glycated albumin and 1,5-AG have excellent performance. Expanded use of these tests has the potential to improve diabetes care as these measures may overcome limitations of HbA1c in certain patients, complement traditional measures by providing additional information on shorter-term glycemic control, and improve risk stratification for diabetes and its complications. Nonetheless, studies are needed to demonstrate if their routine use will benefit patients and improve outcomes.

show abstract

“…Furthermore, the agent provides improvements in glycemic control [17]. DPP-4 inhibitors-related studies on humans have found a decrease in HbA1c levels [18]. It has been reported that DPP-4 inhibitors do not affect body weight [19].…”

mentioning

confidence: 99%

Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats

Karabulut

Coşkun

Bolkent

2015

Pharmacological Reports

View full text Add to dashboard Cite

show abstract

Glycated Albumin (GA) is More Advantageous than Hemoglobin A1c for Evaluating the Efficacy of Sitagliptin in Achieving Glycemic Control in Patients with Type 2 Diabetes

Cited by 7 publications

References 21 publications

Advantages and Pitfalls of Fructosamine and Glycated Albumin in the Diagnosis and Treatment of Diabetes

Advantages and Pitfalls of Fructosamine and Glycated Albumin in the Diagnosis and Treatment of Diabetes

Beyond HbA1c and Glucose: the Role of Nontraditional Glycemic Markers in Diabetes Diagnosis, Prognosis, and Management

Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats

Contact Info

Product

Resources

About